WSI Co

WSI Co EBITDA per Share

The EBITDA per Share of WSI Co (299170.KQ) as of Oct 16, 2026 is 94.33 KRW. In the previous year, EBITDA per Share was 160.92 KRW — a change of -41.38% (lower).

EBITDA per Share

94.33KRW

YoY

-41.38%

Last updated:

EBITDA per Share of WSI Co is 2025 94.33 KRW. EBITDA per Share of WSI Co was 2024 160.92 KRW. It decreases by -41.38% lower compared to the previous year.

The WSI Co EBITDA per Share history

  • 3 Years

  • 10 Years

  • 25 Years

  • Max

EBITDA per Share
Date
EBITDA per Share
Jan 1, 2018
-1.43 KRW
Jan 1, 2019
-1.28 KRW
Jan 1, 2020
168.24 KRW
Jan 1, 2021
196.53 KRW
Jan 1, 2022
137.08 KRW
Jan 1, 2023
169.04 KRW
Jan 1, 2024
160.92 KRW
Jan 1, 2025
94.33 KRW
The WSI Co EBITDA per Share history
YEAREBITDA per ShareYoY
94.33KRW-41.38%
160.92KRW-4.80%
169.04KRW+23.32%
137.08KRW-30.25%
196.53KRW+16.81%
168.24KRW-13,262.43%
-1.28KRW-10.77%
-1.43KRW—

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

WSI Co Stock analysis

What does WSI Co do? WSI Co Ltd is a South Korean company operating in the health care sector, headquartered in Seoul. The company went public on September 21, 2018, with a ticker symbol of 299170.KQ and ISIN KR7299170001. WSI Co Ltd manufactures medical devices and pharmaceutical products, focusing on specific therapeutic areas. The company distributes a topical hemostatic agent called Flosils. It also supplies endoscopes used in spinal surgery, anti-adhesion agents, and bone hemostatic agents. WSI Co Ltd's business activities are centered around medical devices and pharmaceuticals, with an emphasis on products that address hemostasis and surgical procedures. The company's website is https://wsi-healthcare.com/, where further information about its products and services may be found. As a publicly listed company, WSI Co Ltd operates within the South Korean financial market and serves customers primarily in the health care industry. The company's product portfolio includes both medical devices and pharmaceuticals, targeting specific clinical applications such as surgical hemostasis and spinal procedures. There is no indication of additional product lines or services beyond those mentioned in the source description. The company's operations are based in Seoul, South Korea, and it has been publicly traded since 2018. WSI Co is one of the most popular companies on Eulerpool.

Frequently Asked Questions about WSI Co stock

EBITDA per Share of WSI Co is 94.33 KRW in 2025.

EBITDA per Share of WSI Co changed from 160.92 KRW to 94.33 KRW, representing a -41.38% change. The value is lower than the previous year.

On Eulerpool you can find the complete historical development of EBITDA per Share WSI Co since 2006 – with annual values, charts, and detailed analysis.

EBITDA per share divides EBITDA by shares outstanding, showing the operating cash earnings allocated to each share before depreciation and financing effects.

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Income Statement — WSI Co

All Key Metrics — WSI Co